On October 17, 2022, Inversago Pharma announced it had completed its $95 million Series C financing round led by New Enterprise Associates with participation from Forbion’s Growth Opportunities Fund, Amgen Ventures, Forbion’s Ventures Fund IV, Fonds de solidarité FTQ, Genesys Capital, AmorChem, JDRF T1D Fund and adMare BioInnovations. Proceeds from the financing round will be used to move Inversago’s lead program, INV-202, into a Phase 2 clinical trial in Diabetic Kidney Disease in Q4 2022.
Inversago Pharma is a Montreal-based, privately owned biotech company at clinical stage, specializing in the development of new therapies focusing on CB1 blockade.
Osler, Hoskin & Harcourt LLP advised Inversago Pharma with a team consisting of Nathalie Beauregard, Calvin Leung, Yulia Yugay, Calvin Leung (Emerging and High Growth Companies) and Joshua Blatt (Corporate).